Overview
Funds raised 1
| Date | Fund size | Announcement |
| Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 17
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Sep 18, 2017 | LifeMine Therapeutics Closes $55M Series A | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boy... |
| Sep 18, 2017 | Arch Ventures Joins $55M Series A for LifeMine Therapeutics | LifeMine Therapeutics today announced the closing of a $55 million Series A financing. The round was led by WuXi Healthcare Ventures with an investor syndicate comprised of Foresite Capital, GV (formerly Google Ventures), Arch Ventures, Boy... |
| May 31, 2017 | $420M fund comes to LYFE, with plans for a trans-Pacific investment strategy introducing US biotechs to China | Less than two years after its launch, Shanghai-based LYFE Capital has come up with an upsized biotech venture fund. And this time it’s spreading its wings directly into the US market, where it plans to start making some new bets... |
| May 29, 2017 | Ge Li melds WuXi VC with Frontline, creating an $800M trans-Pacific powerhouse fund now hunting fresh biotech capital | WuXi’s Ge Li is leveraging up a whole new biotech venture group with ambitious plans to add to the hundreds of millions of dollars it’s invested in global biotechs. Ge Li Ge Li is throwing in his portfolio of 40 biotechs at Wu... |
| Jul 4, 2016 | Chinese biopharma firm CStone gets $150m Series A from Oriza, Boyu, WuXi | Premium Oriza Seed Venture Capital, Boyu Capital and WuXi Healthcare Ventures have jointly invested in a bio-pharmaceutical firm CStone Pharmaceuticals’ series A financing round of $150 million, the companies said in a statement. Continue r... |
| Jul 3, 2016 | CStone Pharmaceuticals Receives $150M in Series A from WuXi Healthcare | CStone Pharmaceuticals Co., Ltd (CStone), a bio-pharmaceutical company devoted to developing new treatments in a range of therapeutic areas, announced that it has closed its Series A round of 150 million dollars financing (about 975 million... |
| May 11, 2016 | WuXi Healthcare Ventures Adds Gregory Verdine as Newest Venture Partner | WuXi Healthcare Ventures, a Shanghai and Boston-based cross-border venture capital firm focused on the life sciences and healthcare fields, has added Gregory Verdine, Ph.D., as its newest Venture Partner. Dr. Verdine, Erving Professor at Ha... |
| Feb 7, 2016 | 23andMe’s position on genomic diversity, international expansion | Ethnicity? Predominantly Western European, 23andMe President Andy Page said in an interview. Part of that, of course, is because most of its million-plus users are stateside. However, 23andMe plans on international expansion – to broaden th... |
| Jan 29, 2016 | China’s Qiming Venture Partners closing $650M fund, reaches $600M in healthcare investments | The company says it has invested more than $600 million in the healthcare sector in the past seven years. In 2014, it invested in a dozen healthcare startups, offering an average of $10 million to each, it said in a statement. “Qiming curre... |
Reviews 0
FAQ about WuXi Healthcare Ventures
What funds has WuXi Healthcare Ventures raised?
WuXi Healthcare Ventures has announced 1 fund on Parsers VC.
What has the press written about WuXi Healthcare Ventures?
Parsers VC has collected 17 articles mentioning WuXi Healthcare Ventures, among them “LifeMine Therapeutics Closes $55M Series A” (Sep 18, 2017) and “Arch Ventures Joins $55M Series A for LifeMine Therapeutics” (Sep 18, 2017).
Is WuXi Healthcare Ventures still active?
WuXi Healthcare Ventures is probably closed: its latest activity on Parsers VC dates from Oct 5, 2017.